Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study

References

• World Health Organisation (WHO). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed on 16 May 2020.
   Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–36. https://doi.org/10.1001/jama.2020.6019.
   PubMed Web of Science ®Google Scholar
• Eguale T, Buckeridge DL, Verma A, et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2016;176(1):55–63. https://doi.org/10.1001/jamainternmed.2015.6058.
   PubMed Web of Science ®Google Scholar
• Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. Natl Sci Rev. 2020;7(9):1428–36. https://doi.org/10.1093/nsr/nwaa113.
   PubMed Web of Science ®Google Scholar
• Gérard A, Romani S, Fresse A, et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies. 2020;75(4):371–9. https://doi.org/10.1016/j.therap.2020.05.002.
   PubMed Web of Science ®Google Scholar
• Sun J, Deng X, Chen X, et al. Incidence of adverse drug reactions in COVID-19 patients in China: an active monitoring study by hospital pharmacovigilance system. Clin Pharmacol Ther. 2020;108(4):791–7. https://doi.org/10.1002/cpt.1866.
   PubMed Web of Science ®Google Scholar
• National Pharmaceutical Regulatory Agency. Malaysian pharmacovigilance guidelines. 2nd edition. https://www.npra.gov.my/images/Guidelines_Central/Guidelines_on_Reporting_and_Monitoring%20_(MADRAC)/Malaysian_Pharmacovigilance_Guidelines_2nd_Edition_2016.pdf. Accessed 20 Apr 2021.
   Google Scholar
• Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J. 2014;22(2):83–94. https://doi.org/10.1016/j.jsps.2013.02.003.
   PubMed Web of Science ®Google Scholar
• Schatz SN, Weber RJ. Adverse drug reactions. In: Murphy JE, Lee MW, editors. PSAP 2015 Book 2 CNS/pharmacy practice: pharmacotherapy self-assessment program. New York: American College of Clinical Pharmacy; 2015. p. 5–21.
   Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006;29:385–96. https://doi.org/10.2165/00002018-200629050-00003.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Malaysia. Clinical Management of Confirmed COVID-19 Case in Adult (Annex 2E). Version 24 March 2021.
   Google Scholar
• Drew BJ, Ackerman MJ, Funk M, et al. Prevention of Torsade de Pointes in hospital settings. J Am Coll Cardiol. 2010;55(9):934–47. https://doi.org/10.1161/CIRCULATIONAHA.109.192704.
   PubMed Web of Science ®Google Scholar
• Association E. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222–61. https://doi.org/10.1016/j.jhep.2019.02.014.
   PubMed Web of Science ®Google Scholar
• Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78(6):743–50. https://doi.org/10.1001/jamainternmed.2015.6058.
   PubMed Web of Science ®Google Scholar
• Visentin GP, Chao YL. Drug Induced Thrombocytopenia. Hematol Oncol Clin N Am. 2007;21(4):685–96, vi. https://doi.org/10.1016/j.hoc.2007.06.005.
   PubMed Web of Science ®Google Scholar
• Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematol Am Soc Hematol Educ Progr. 2017;1:187–93. https://doi.org/10.1182/asheducation-2017.1.187.
   Google Scholar
• Salem CB, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricemia and gout. Rheumatology. 2016;56(5):679–88. https://doi.org/10.1093/rheumatology/kew293.
   Web of Science ®Google Scholar
• Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol. 2004;19(11):1312–7. https://doi.org/10.1111/j.1440-1746.2004.03459.x.
   PubMed Web of Science ®Google Scholar
• World Health Organization-Uppsala Monitoring Centre (WHO-UMC). The use of the WHO-UMC system for standardised case causality assessment. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Accessed 22 Apr 2021.
   Google Scholar
• ICH Steering Committee. Clinical safety data management: definitions and standards for expedited reporting E2A. https://www.crc.gov.my/wp-content/uploads/documents/ICH%20E2A.pdf. Accessed 22 Apr 2021.
   Google Scholar
• Cano FG, Rozenfeld S. Adverse drug events in hospitals: a systematic review. Cad Saude Publica. 2009;25(suppl 3):S360–72. https://doi.org/10.1590/s0102-311x2009001500003.
   PubMedGoogle Scholar
• Melo JRR, Duarte EC, de Moraes MV, et al. Adverse drug reactions in patients with COVID-19 in Brazil: analysis of spontaneous notifications of the Brazilian pharmacovigilance system. Cad Saude Publica. 2021;37(1):e00245820.
   PubMed Web of Science ®Google Scholar
• Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4(2):e4439. https://doi.org/10.1371/journal.pone.0004439.
   PubMed Web of Science ®Google Scholar
• Dupouy J, Moulis G, Tubery M, et al. Which adverse events are related to health care during hospitalization in elderly inpatients? Int J Med Sci. 2013;10(9):1224–30. https://doi.org/10.7150/ijms.6640.
   PubMed Web of Science ®Google Scholar
• Giardina C, Cutroneo PM, Mocciaro E, et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward) study. Front Pharmacol. 2018;9:350. https://doi.org/10.3389/fphar.2018.00350.
   PubMed Web of Science ®Google Scholar
• Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with adverse drug reactions following hospital admission. Drug Saf. 2008;31(9):789–98. https://doi.org/10.2165/00002018-200831090-00007.
   PubMed Web of Science ®Google Scholar
• Muñoz-Torrero JF, Barquilla P, Velasco R, et al. Adverse drug reactions in internal medicine units and associated risk factors. Eur J Clin Pharmacol. 2010;66(12):1257–64. https://doi.org/10.1007/s00228-010-0866-6.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Malaysia. Malaysian consensus guidelines on antiretroviral therapy. https://www.researchgate.net/publication/319101215_Malaysian_Consensus_Guidelines_on_Antiretroviral_Therapy_2017_MINISTRY_OF_HEALTH_MALAYSIA. Accessed 20 Apr 2021.
   Google Scholar
• VigiAccess. http://www.vigiaccess.org/. Accessed 22 Apr 2021.
   Google Scholar
• Reyataz® Product Insert. Revised October 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf. Accessed 22 Apr 2021.
   Google Scholar
• Kaletra® Product Insert. Revised November 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021251s052_021906s046lbl.pdf. Accessed 22 Apr 2021.
   Google Scholar
• Haider N, Mazhar F. Factors associated with underreporting of adverse drug reactions by nurses: a narrative literature review. Saudi J Health Sci. 2017;6(2):71–6.
   Google Scholar
• Hofer-Dueckelmann C, Prinz E, Beindl W, et al. Adverse drug reactions (ADRs) associated with hospital admissions—elderly female patients are at highest risk. Int J Clin Pharmacol Ther. 2011;49(10):577–86. https://doi.org/10.5414/cp201514.
   PubMed Web of Science ®Google Scholar
• Varallo FR, Guimarães SOP, Abjaude SAR, Mastroianni PC. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Rev Esc Enferm USP. 2014;48(4):739–47. https://doi.org/10.1590/s0080-623420140000400023.
   PubMed Web of Science ®Google Scholar
• National Pharmaceutical Regulatory Agency. 2018 Annual report National Centre for adverse drug reactions monitoring. https://npra.gov.my/easyarticles/images/users/1108/Annual%20Report/AR2018.pdf. Accessed 22 Apr 2021.
   Google Scholar
• World Health Organization. Clinical management of severe acute respiratory infection (‎SARI)‎ when COVID-19 disease is suspected: interim guidance, 13 March 2020. https://apps.who.int/iris/handle/10665/331446.
   Google Scholar
• World Health Organization. Therapeutics and COVID-19: living guideline. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1. Accessed 22 Apr 2021.
   Google Scholar